A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly/Biweekly Dosing in Treatment-Experienced Patients and Loading/Weekly Maintenance Dosing in Treatment-Naïve Patients with Primary Immunodeficiency
Journal of Clinical Immunology · 2025
DOI: 10.1007/s10875-025-01952-5 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Clinical Immunology, 2025. Verfasst von William R Lumry und 12 weiteren Autor:innen. Beteiligte Einrichtung: Allergy and Asthma Research Association Research Center, Dallas, 10100 N. Central Expressway, Suite 100, TX, 75231, USA. Lumrymd@aararesearch.com. Hauptthemen laut MEDLINE: Immunologic Deficiency Syndromes, Immunoglobulins, Intravenous, Immunoglobulins, Primary Immunodeficiency Diseases. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Grifols.
Abstract (Originalsprache)
Intravenous immunoglobulin (IVIG) therapy is a well-documented and effective treatment for primary immunodeficiencies (PI). Subcutaneous immunoglobulins (SCIG) have emerged as an effective alternative for some patients that offers additional flexibility.Currently, caprylate/chromatography purified IGSC (human) 20% is approved to treat PI in North America and many countries worldwide. In this multi-center, open-label study, the pharmacokinetics (PK), efficacy, and safety of IGSC 20% were studied after biweekly (every two weeks) dosing for 16 weeks and compared to weekly IGSC 20% administration for 16 weeks in treatment-experienced PI patients. A loading/weekly maintenance SC regimen was also studied in PI patients naïve to IG treatment.In treatment-experienced patients, the least squares mean ratio of steady-state AUC0−7 days for biweekly dosing showed non-inferiority to weekly dosing (90% confidence interval 1.0030–1.0685). Other PK parameters (Cmax, Tmax, steady state trough) were similar between treatments. Efficacy and safety measures were qualitatively similar to previously published results. No serious bacterial infections were reported. Annual rates for any type of infection were similar between the treatment groups. All severe treatment-related adverse events (AEs) were unrelated to treatment. Only mild to moderate suspected adverse drug reactions were observed.PK analyses showed that biweekly dosing of IGSC 20% was non-inferior to weekly dosing in treatment-experienced PI patients. Biweekly dosing had similar patterns to weekly in prevention of serious bacterial infections, rates of all infections and hospitalizations for infections. The IGSC loading/maintenance dosing regimen in naïve patients was safe and effective during the observation period.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Allergy and Asthma Research Association Research Center, Dallas, 10100 N. Central Expressway, Suite 100, TX, 75231, USA. Lumrymd@aararesearch.com.
- Allergy & Clinical Immunology Associates, Pittsburgh, PA, USA.
- Allergy & Immunology, Research Solutions of Arizona, Litchfield, AZ, USA.
- Allergy, Asthma & Immunology Center, Vital Prospects Clinical Research Institute, Tulsa, OK, USA.
- Optimed Research Ltd, Columbus, OH, USA.
- Allergy & Asthma Clinics of Georgia, Georgia Pollens Clinical Research Centers, Albany, GA, USA.
Förderung
- Grifols
Zitieren
APA
Lumry, W. R., Palumbo, M., Hsu, C., Hussain, I., McNeil, D., Bridges, T., Wedner, H. J., Scarupa, M., Mondou, E., Nanaware-Kharade, N., Hanna, K., Coll, M. Q., & Oliveras, J. (2025). A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly/Biweekly Dosing in Treatment-Experienced Patients and Loading/Weekly Maintenance Dosing in Treatment-Naïve Patients with Primary Immunodeficiency. Journal of Clinical Immunology. https://doi.org/10.1007/s10875-025-01952-5
Vancouver
Lumry WR, Palumbo M, Hsu C, Hussain I, McNeil D, Bridges T, et al. A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly/Biweekly Dosing in Treatment-Experienced Patients and Loading/Weekly Maintenance Dosing in Treatment-Naïve Patients with Primary Immunodeficiency. Journal of Clinical Immunology. 2025. doi:10.1007/s10875-025-01952-5
BibTeX
@article{Lumry2025,
author = {Lumry, William R and Palumbo, Michael and Hsu, Connie and Hussain, Iftikhar and McNeil, Donald and Bridges, Tracy and Wedner, H James and Scarupa, Mark and Mondou, Elsa and Nanaware-Kharade, Nisha and Hanna, Kim and Coll, Montse Querolt and Oliveras, Juan},
title = {A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly/Biweekly Dosing in Treatment-Experienced Patients and Loading/Weekly Maintenance Dosing in Treatment-Naïve Patients with Primary Immunodeficiency},
journal = {Journal of Clinical Immunology},
year = {2025},
doi = {10.1007/s10875-025-01952-5}
}
EUVIMED